MLICM
STIM icon

Metropolitan Life Insurance Company (MetLife)’s Neuronetics STIM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,710
Closed -$124K – 2852
2021
Q2 		$124K Buy
+7,710
New +$107K ﹤0.01% 2484

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s STIM Position: Q3 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Neuronetics (STIM) in Q3 2021, closing a stake of 7,710 shares — an estimated $124K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in STIM in Q2 2021 and held it in 1 quarter. The position peaked at $124K in Q2 2021. 97 funds tracked by Wall St. Rank hold STIM as of Q3 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Neuronetics position as of Q3 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 7,710 Neuronetics shares in Q3 2021, an estimated $124K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Neuronetics in Q2 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Neuronetics position peaked at $124K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Neuronetics as of Q3 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2021, filed 15 Nov 2021.